Thursday,
June 11, 2020
 
LSBC  NEWS
Recent LSBC Activities

 
  • BIO 2020 Virtual Conference: This year BIO is virtual and as part of the week-long conference LSBC hosted a BC Event with Deputy Minister Fazil Mihlar of the Ministry of Jobs, Economic Development and Competitiveness. The BC event was captured on Zoom and you can watch it here.
Note:When available, going forward, videos of LSBC events will be posted to coincide with our activites
COVID 19 RESOURCES

BRITISH COLUMBIA


CANADA

MEMBER  News
 Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
VICTORIA, British Columbia-(BUSINESS WIRE)-Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented.  READ MORE
Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal


MONTREALJune 8, 2020 /CNW Telbec/ - CTI Life Sciences, along with partners adMare BioInnovations, Domain Therapeutics and PeptiMimesis Pharma, have come together to establish a new  Montreal-based drug discovery and development company, Find Therapeutics, dedicated to the development of the next generation of GPCR allosteric modulators to treat rare diseases.  READ MORE
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020

VICTORIA, British Columbia-(BUSINESS WIRE)- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that additional safety data from the completed AURORA pivotal trial of voclosporin ..... READ MORE
CSL Behring to Acquire Biotech Company Vitaeris

 

KING OF PRUSSIA, Pa. , June 8, 2020 /PRNewswire/ - Global biotherapeutics leader  CSL Behring  announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.  READ MORE
DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline  


SAN DIEGO & PRINCETON, N.J., June 10, 2020 /PRNewswire/ - DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar") and Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") today announced the companies have entered into a definitive merger agreement pursuant to which DelMar, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, will acquire Adgero.... READ MORE
 COVID 19 - Industry NEWS
Health Research Foundation of Innovative Medicines Canada Chair in Pandemic Preparedness Research


June 11, 2020 | The Health Research Foundation of Innovative Medicines Canada invites applications for the Health Research Foundation of Innovative Medicines Canada Chair in Pandemic Preparedness Research .   READ MORE
Lilly says COVID-19 treatment could be authorized for use as soon as September
June 10, 2020 | VINCENT KESSLER/REUTERS  Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told Reuters on Wednesday.  READ MORE
Johnson & Johnson moves up start of coronavirus vaccine human trials to July
 
June 10, 2020 | Globe and Mail | Johnson & Johnson moved up the start of human clinical trials for its experimental vaccine against the highly contagious coronavirus by two months to the second half of July, as the drugmaker rushes to develop a prevention for COVID-19, the company said on Wednesday.   READ MORE
 EMPLOYMENT OPPORTUNITIES and PROGRAMS
Lab Technician  ViroGin Biotech Canada Ltd.
Software Development LeadLibang Surgical Technologies
What could your company do with $20,000 in wage subsidies?

Wage Subsidies for Hiring Young Talent 
The Career Starter Program facilitates the transition for youth facing challenges entering the labour market and increases their knowledge of the sector's needs through recent and practical work experience. The program provides 50% of the youth's salary to a maximum of $20,000 in wage subsidies for a 3 to 9-months placement. 
Are you eligible? 
As a resource to the bio-economy, BioTalent Canada is continuing its operations virtually including accepting wage subsidy applications, and processing claims as quickly as possible. Employers, uncertain if your job qualifies or would like to be pre-qualified before you hire?
Contact: 
Sue Callaghan:  scallaghan@biotalent.ca
Did you know  LifeSciences BC's Job Board  gets 
approximately 60,000 visitors a month?
~
LSBC Membership Discounts on Job Postings
 
As an LSBC member, your first five job postings EARNS a free repost on Biotalent's  The Petri Dish?
After your first five reposts, you will also receive 25% off all job postings on  The Petri Dish!
 
Want more info? Please contact Sue Callaghan at
 LSBC NOTICE  
DUE TO THE COVID 19 VIRUS, LIFESCIENCES BC STAFF ARE WORKING FROM HOME.  WE WILL RETURN  TO NORMAL WORKING CONDITIONS ONCE GOVERNMENT HAS SAID IT IS SAFE TO DUE SO.

UNTIL THEN, WE ARE ALL REACHABLE BY EMAIL LISTED HERE
In This Issue
Platinum Sponsors
GOLD SPONSORS
SILVER SPONSORS
BRONZE SPONSORS







Suite 580-1285 West Broadway 
Vancouver, BC V6H 3X8
604 669-9909
admin@lifesciencesbc.ca